Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The immunohistochemical (IHC) evaluation of estrogen receptor (ER), progesterone receptor (PgR), Ki-67 and HER2 is considered a surrogate means for identifying the molecular subtypes of breast cancer with different prognosis. We explored patterns of recurrence in 4837 women with breast cancer defined as Luminal B (ER-positive and/or PgR-positive, HER2 positive and/or Ki-67≥14%) by IHC classification. We evaluated four subgroups within the Luminal B subtype according to HER2 expression and PgR status. Patients within the ER+/PgR+/HER2- subgroup presented a 5-year breast cancer-related survival (BCS) of 97% (95% confidence interval (CI), 96-97) and overall survival (OS) of 95% [95% CI, 95-96], the best survivals of the Luminal B subgroups. In the multivariate analysis, the ER+/PgR-/HER2- subgroup was associated with a reduced BCS (HR 1.71; 95%CI, 1.25-2.35) and OS (HR 1.47; 95%CI, 1.10-1.96) when compared with the ER+/PgR+/HER2- subgroup. Also patients within the ER+/PgR-/HER2+ subgroup had a reduced BCS (HR 1.93; 95%CI, 1.32-2.83) and OS (HR 1.62; 95%CI, 1.14-2.30) when compared with ER+/PgR+/HER2- subgroup. On the other hand, no statistically significant differences were found with regard to BCS and OS among patients with ER+/PgR+/HER2+ and patients with ER+/PgR+/HER2- disease. PgR loss identifies Luminal B breast cancer subgroups at higher risk of relapse and death, both with HER-2-positive and HER-2-negative disease.

Original languageEnglish
Pages (from-to)661-668
Number of pages8
JournalAnnals of Oncology
Volume24
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Progesterone Receptors
Estrogen Receptors
Breast Neoplasms
Recurrence
Survival
Confidence Intervals
Multivariate Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{25b39dbe3d4e433dbf03f2720e10f9dc,
title = "Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.",
abstract = "The immunohistochemical (IHC) evaluation of estrogen receptor (ER), progesterone receptor (PgR), Ki-67 and HER2 is considered a surrogate means for identifying the molecular subtypes of breast cancer with different prognosis. We explored patterns of recurrence in 4837 women with breast cancer defined as Luminal B (ER-positive and/or PgR-positive, HER2 positive and/or Ki-67≥14{\%}) by IHC classification. We evaluated four subgroups within the Luminal B subtype according to HER2 expression and PgR status. Patients within the ER+/PgR+/HER2- subgroup presented a 5-year breast cancer-related survival (BCS) of 97{\%} (95{\%} confidence interval (CI), 96-97) and overall survival (OS) of 95{\%} [95{\%} CI, 95-96], the best survivals of the Luminal B subgroups. In the multivariate analysis, the ER+/PgR-/HER2- subgroup was associated with a reduced BCS (HR 1.71; 95{\%}CI, 1.25-2.35) and OS (HR 1.47; 95{\%}CI, 1.10-1.96) when compared with the ER+/PgR+/HER2- subgroup. Also patients within the ER+/PgR-/HER2+ subgroup had a reduced BCS (HR 1.93; 95{\%}CI, 1.32-2.83) and OS (HR 1.62; 95{\%}CI, 1.14-2.30) when compared with ER+/PgR+/HER2- subgroup. On the other hand, no statistically significant differences were found with regard to BCS and OS among patients with ER+/PgR+/HER2+ and patients with ER+/PgR+/HER2- disease. PgR loss identifies Luminal B breast cancer subgroups at higher risk of relapse and death, both with HER-2-positive and HER-2-negative disease.",
author = "G. Cancello and P. Maisonneuve and N. Rotmensz and G. Viale and Mastropasqua, {M. G.} and G. Pruneri and E. Montagna and M. Iorfida and M. Mazza and A. Balduzzi and P. Veronesi and A. Luini and M. Intra and A. Goldhirsch and M. Colleoni",
year = "2013",
month = "3",
doi = "10.1093/annonc/mds430",
language = "English",
volume = "24",
pages = "661--668",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.

AU - Cancello, G.

AU - Maisonneuve, P.

AU - Rotmensz, N.

AU - Viale, G.

AU - Mastropasqua, M. G.

AU - Pruneri, G.

AU - Montagna, E.

AU - Iorfida, M.

AU - Mazza, M.

AU - Balduzzi, A.

AU - Veronesi, P.

AU - Luini, A.

AU - Intra, M.

AU - Goldhirsch, A.

AU - Colleoni, M.

PY - 2013/3

Y1 - 2013/3

N2 - The immunohistochemical (IHC) evaluation of estrogen receptor (ER), progesterone receptor (PgR), Ki-67 and HER2 is considered a surrogate means for identifying the molecular subtypes of breast cancer with different prognosis. We explored patterns of recurrence in 4837 women with breast cancer defined as Luminal B (ER-positive and/or PgR-positive, HER2 positive and/or Ki-67≥14%) by IHC classification. We evaluated four subgroups within the Luminal B subtype according to HER2 expression and PgR status. Patients within the ER+/PgR+/HER2- subgroup presented a 5-year breast cancer-related survival (BCS) of 97% (95% confidence interval (CI), 96-97) and overall survival (OS) of 95% [95% CI, 95-96], the best survivals of the Luminal B subgroups. In the multivariate analysis, the ER+/PgR-/HER2- subgroup was associated with a reduced BCS (HR 1.71; 95%CI, 1.25-2.35) and OS (HR 1.47; 95%CI, 1.10-1.96) when compared with the ER+/PgR+/HER2- subgroup. Also patients within the ER+/PgR-/HER2+ subgroup had a reduced BCS (HR 1.93; 95%CI, 1.32-2.83) and OS (HR 1.62; 95%CI, 1.14-2.30) when compared with ER+/PgR+/HER2- subgroup. On the other hand, no statistically significant differences were found with regard to BCS and OS among patients with ER+/PgR+/HER2+ and patients with ER+/PgR+/HER2- disease. PgR loss identifies Luminal B breast cancer subgroups at higher risk of relapse and death, both with HER-2-positive and HER-2-negative disease.

AB - The immunohistochemical (IHC) evaluation of estrogen receptor (ER), progesterone receptor (PgR), Ki-67 and HER2 is considered a surrogate means for identifying the molecular subtypes of breast cancer with different prognosis. We explored patterns of recurrence in 4837 women with breast cancer defined as Luminal B (ER-positive and/or PgR-positive, HER2 positive and/or Ki-67≥14%) by IHC classification. We evaluated four subgroups within the Luminal B subtype according to HER2 expression and PgR status. Patients within the ER+/PgR+/HER2- subgroup presented a 5-year breast cancer-related survival (BCS) of 97% (95% confidence interval (CI), 96-97) and overall survival (OS) of 95% [95% CI, 95-96], the best survivals of the Luminal B subgroups. In the multivariate analysis, the ER+/PgR-/HER2- subgroup was associated with a reduced BCS (HR 1.71; 95%CI, 1.25-2.35) and OS (HR 1.47; 95%CI, 1.10-1.96) when compared with the ER+/PgR+/HER2- subgroup. Also patients within the ER+/PgR-/HER2+ subgroup had a reduced BCS (HR 1.93; 95%CI, 1.32-2.83) and OS (HR 1.62; 95%CI, 1.14-2.30) when compared with ER+/PgR+/HER2- subgroup. On the other hand, no statistically significant differences were found with regard to BCS and OS among patients with ER+/PgR+/HER2+ and patients with ER+/PgR+/HER2- disease. PgR loss identifies Luminal B breast cancer subgroups at higher risk of relapse and death, both with HER-2-positive and HER-2-negative disease.

UR - http://www.scopus.com/inward/record.url?scp=84880789122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880789122&partnerID=8YFLogxK

U2 - 10.1093/annonc/mds430

DO - 10.1093/annonc/mds430

M3 - Article

VL - 24

SP - 661

EP - 668

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -